Abstract
In recent times, there has been an increased use of software and computational models in Medicinal Chemistry, both for the prediction of effects such as drug-target interactions, as well as for the development of (Quantitative) Structure-Activity Relationships ((Q)SAR). Whilst the ultimate goal of Medicinal Chemistry research is for the discovery of new drug candidates, a secondary yet important outcome that results is in the creation of new computational tools. The adoption of computational tools by medicinal chemists is sadly, and all too often accompanied, by a lack of understanding of the legal aspects related to software and model use, that is, the copyright protection of new medicinal chemistry software and software-mediated discovered products. This article aims to provide a reference to the various legal avenues that are available for the protection of software, and the acceptance and legal treatment of scientific results and techniques derived from such software. An overview of relevant international tax issues is also presented. We have considered cases of patents protecting software, models, and/or new compounds discovered using methods such as molecular modeling or QSAR. This paper has been written and compiled by the authors as a review of current topics and trends on the legal issues in certain fields of Medicinal Chemistry and as such is not intended to be exhaustive.
Keywords: Computational medicinal chemistry legal issues, Software protection, QSAR Copyright, tax issues
Current Topics in Medicinal Chemistry
Title: Current Topics on Software Use in Medicinal Chemistry: Intellectual Property, Taxes, and Regulatory Issues
Volume: 8 Issue: 18
Author(s): Aliuska Duardo-Sanchez, Grace Patlewicz and Antonio Lopez-Diaz
Affiliation:
Keywords: Computational medicinal chemistry legal issues, Software protection, QSAR Copyright, tax issues
Abstract: In recent times, there has been an increased use of software and computational models in Medicinal Chemistry, both for the prediction of effects such as drug-target interactions, as well as for the development of (Quantitative) Structure-Activity Relationships ((Q)SAR). Whilst the ultimate goal of Medicinal Chemistry research is for the discovery of new drug candidates, a secondary yet important outcome that results is in the creation of new computational tools. The adoption of computational tools by medicinal chemists is sadly, and all too often accompanied, by a lack of understanding of the legal aspects related to software and model use, that is, the copyright protection of new medicinal chemistry software and software-mediated discovered products. This article aims to provide a reference to the various legal avenues that are available for the protection of software, and the acceptance and legal treatment of scientific results and techniques derived from such software. An overview of relevant international tax issues is also presented. We have considered cases of patents protecting software, models, and/or new compounds discovered using methods such as molecular modeling or QSAR. This paper has been written and compiled by the authors as a review of current topics and trends on the legal issues in certain fields of Medicinal Chemistry and as such is not intended to be exhaustive.
Export Options
About this article
Cite this article as:
Duardo-Sanchez Aliuska, Patlewicz Grace and Lopez-Diaz Antonio, Current Topics on Software Use in Medicinal Chemistry: Intellectual Property, Taxes, and Regulatory Issues, Current Topics in Medicinal Chemistry 2008; 8 (18) . https://dx.doi.org/10.2174/156802608786786606
DOI https://dx.doi.org/10.2174/156802608786786606 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets Recent Strategies in the Search for New Anti-Influenza Therapies
Current Drug Targets Insights into the Zinc-Dependent Deacetylase LpxC: Biochemical Properties and Inhibitor Design
Current Topics in Medicinal Chemistry Pathophysiology of SARS-CoV2 Mediated Depression, Therapeutics, and Consequences: A Comprehensive Narrative
Mini-Reviews in Medicinal Chemistry B-Cell Lymphoma Associated with COVID‐19 Infection: A Case Report
Current Medical Imaging Targeting the Ubiquitin Proteasome System: Beyond Proteasome Inhibition
Current Pharmaceutical Design New Highly Potent and Selective Adenosine A3 Receptor Antagonists
Current Topics in Medicinal Chemistry Agonists and Antagonists of Protease Activated Receptors (PARs)
Current Medicinal Chemistry Monooxime Bispyridinium Reactivators Bearing Xylene Linker Synthesis and In Vitro Evaluation on Model of Organophosphate-Inhibited Acetylcholinesterase
Medicinal Chemistry Role of Sulfonamide Group in Matrix Metalloproteinase Inhibitors
Current Medicinal Chemistry Editorial: Computer-assisted Vaccine Design (CAVD) Approach can Help in the Management of the Emerging H7N9 Influenza Virus
Current Computer-Aided Drug Design Antiviral Activities of Human Host Defense Peptides
Current Medicinal Chemistry Evaluation and Prediction of End of Second-wave and Starting of Thirdwave Covid-19 Cases in India
Current Signal Transduction Therapy Anti-Inflammatory Activity and Cheminformatics Analysis of New Potent 2-Substituted 1-Methyl-5-Nitroindazolinones
Current Topics in Medicinal Chemistry Antineoplastic Potential of Medicinal Plants
Recent Patents on Biotechnology Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence
Current Pharmaceutical Design Analyses of Protein Sequences Using Inter-Residue Average Distance Statistics to Study Folding Processes and the Significance of Their Partial Sequences
Protein & Peptide Letters Mapping of New Pharmacological Alternatives in the Face of the Emergence of Antibiotic Resistance in COVID-19 Patents Treated for Opportunistic Respiratory Bacterial Pathogens
Recent Advances in Anti-Infective Drug Discovery Further Insights in 5-phenyl-2-[2-(1-piperidinylcarbonyl) Phenyl]-2,3- dihydro-1H-pyrrolo[1,2-c]imidazol-1-ones, a Recently Disclosed Class of Neuropeptide S Antagonists
Letters in Drug Design & Discovery Current Non-viral Gene Therapy Strategies for the Treatment of Glioblastoma
Current Medicinal Chemistry